Autolus Therapeutics to Present at Conferences During January 2022
05 January 2022 - 11:00PM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced that they are scheduled to deliver
a corporate presentation at the following virtual conferences:
- Dr. Lucinda Crabtree, Senior Vice
President, Finance, will present at the H.C. Wainwright BioConnect
Conference, where an on-demand webcast will be available on Monday,
January 10, 2022, starting at 7.00 am ET.
- Dr. Christian Itin, Chief Executive
Officer, will present at the 40th annual J.P. Morgan Healthcare
Conference on Wednesday, January 12, 2022 at 8.15 am ET.
Senior management will participate in virtual
one-on-one meetings with investors at both conferences.
The presentations will be available on the
investor relations section of Autolus’ website at
https://www.autolus.com. An archived replay will be available on
the company’s website for a period of 90 days after the
conferences.
About Autolus Therapeutics
plcAutolus is a clinical-stage biopharmaceutical company
developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular
T cell programming technologies, the Company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information,
please visit www.autolus.com.
Contact:
Lucinda Crabtree, PhDSenior Vice President,
Finance+44 (0) 7587 372 619l.crabtree@autolus.com
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-212-966-3650susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024